COUR NanoParticle technology halts Type 1 diabetes progression
COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, in which treatment with the COUR NanoParticle Platform (CNP) prevented
COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, in which treatment with the COUR NanoParticle Platform (CNP) prevented